Kovina Therapeutics
Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral HPV therapeutics
Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral HPV therapeutics
Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral HPV therapeutics. The company, founded in 2020, aims to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV). Their efforts focus on the Biotechnology and Health and Wellness industries. In November 2022, they received a $275.00K grant investment from the National Institute of Dental and Craniofacial Research (NIDCR).
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $275.00K | 1 | National Institute of Dental and Craniofacial Research (NIDCR) | 01 Nov 2022 |
| Grant | $300.00K | 1 | National Institute of Allergy and Infectious Diseases | 12 Sep 2022 |
| Grant | Unknown | 1 | National Cancer Institute | 27 Jun 2022 |
| Seed Round | $2.00M | 3 |
|
20 Oct 2021 |
No recent news or press coverage available for Kovina Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
